Absci (ABSI) Receivables (2023 - 2025)

Absci's (ABSI) quarterly Receivables came in at $16.0 million in Q3 2025, up 1.91% quarter-over-quarter from $15.7 million in Q2 2025.

Absci (ABSI) Receivables (2023 - 2025) Analysis & Trends

Absci has disclosed Receivables across 3 years of filings, most recently posting $16.0 million for Q3 2025.

  • Receivables for Q3 2025 came in at $16.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $16.0 million (changed N/A YoY), and the FY2024 annual result was $15.0 million, down 12.73% from the prior year.
  • Receivables came in at $16.0 million for Q3 2025 at Absci, up from $15.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $17.2 million in Q4 2023 to a low of $15.0 million in Q4 2024.
  • The 3-year median for Receivables is $16.0 million (2025), against an average of $16.1 million.
  • Peak annual rise in Receivables reached 12.73% in 2024, while the deepest fall reached 12.73% in 2024.
  • Absci's Receivables stood at $17.2 million in 2023, then decreased by 12.73% to $15.0 million in 2024, then rose by 6.67% to $16.0 million in 2025.
  • The last three Receivables figures came in at $16.0 million (Q3 2025), $15.7 million (Q2 2025), and $16.4 million (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 13.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 2.00 Bn
9 Abivax 91.96 Bn 91.96 Bn - -
10 Absci 1.13 Bn 1.01 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 16.00 Mn
Jun 30, 2025 15.70 Mn
Mar 31, 2025 16.38 Mn
Dec 31, 2024 15.00 Mn
Dec 31, 2023 17.19 Mn